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ABSTRACT 
Objective 
The timing of preoperative discontinuation of aspirin for patients undergoing coronary 
artery bypass grafting (CABG) in clinical practice seems to often differ from the 
current guidelines.  We evaluated the effect of timing of aspirin cessation on 
morbidity and early and late mortality. 
Methods 
The timing of aspirin cessation for patients who underwent isolated coronary artery 
bypass grafting (CABG) was analysed using a prospectively collected data obtained 
from the Cardiac Surgery Database of the Australian and New Zealand Society of 
Cardiac and Thoracic Surgeons (ANZSCTS) between 2001, and 2012.  The patients 
were divided into 3 groups; continued to the day of surgery or stopped within 2 days 
prior to surgery (late use), stopped between 3 to 7 days prior to surgery (late 
discontinuation), and stopped more than 7 days prior to surgery (early 
discontinuation).   
Results 
16,988 patients who received aspirin prior to surgery underwent isolated CABG.  
There were 6,814 patients in the late use group, 3,634 in the late discontinuation 
group, and 6,540 in the early discontinuation group.  Compared to the early 
discontinuation and late discontinuation group, the early drain output, and transfusion 
requirements were significantly higher in the late use group.  Reoperation for bleeding 
was associated with late use.  There was no significant difference in the 30-day and in 
hospital mortality. 
 
Conclusions 
Among patients undergoing elective isolated CABG, the timing of aspirin cessation 
was not associated with increased early mortality, but resulted in increased bleeding 
and transfusion requirement.  The late use of preoperative aspirin still remains 
controversial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The administration of Aspirin early after coronary artery bypass grafting (CABG) has 
been shown to improve survival and graft patency, and reduce ischemic complications 
[1].  Guideline from The Society of Thoracic Surgeons (STS) [2] suggests that aspirin 
be discontinued in patients without acute coronary syndrome 3 to 5 days before 
surgery.  On the other hand, the guideline from the American College of 
Cardiology/American Heart Association (ACC/AHA) [3] recommends aspirin to be 
administered preoperatively for CABG patients.  Interestingly, the previous 
ACC/AHA guideline in 2004 suggested that aspirin be discontinued in patients 
without acute coronary syndrome undergoing CABG 7 to 10 days before surgery [4].  
The management of perioperative aspirin dosing varies among surgeons and medical 
institutions especially when it comes to preoperative management.  Backgrounds for 
stopping aspirin include the potential for increased bleeding and transfusion 
requirements during and after surgery [5,6], and a meta-analysis showed that 
preoperative aspirin increases postoperative bleeding, transfusion requirements, and 
chest reexploration for bleeding, while having no significant effect on MI or death [7].   
However, these studies tend to be outdated, and recent studies are starting to show a 
shift in paradigm.  Jacob et al. has reported that patients who had aspirin continued 
within 5 days of surgery (late use) received more intraoperative and postoperative 
transfusion, but a similar number of reoperations for bleeding compared with those 
who had their aspirin discontinued 6 or more days prior to surgery (early 
discontinuation) in patients undergoing CABG [8].  In patients undergoing CABG and 
valve surgery, they have reported that the late use group patients received more 
postoperative transfusions and tended to have increased reoperation for bleeding rate 
than early discontinuation group patients, but no difference in major adverse cardiac 
events [9].  We studied the effect of aspirin continuation prior to CABG on short and 
long term mortality. 
 
METHODS 
We analysed prospectively collected data obtained from the Cardiac Surgery 
Database of the Australian and New Zealand Society of Cardiac and Thoracic 
Surgeons (ANZSCTS).  The data collection and its audit methods were discussed 
previously [10].  Data from this database has been approved for use in research by the 
institutional review board with patient consent waived.  Long term mortality data 
were obtained from the Australian National Death Index which records all deaths 
within Australia.  From June 2001 to December 2012, information on preoperative 
use of aspirin and other antiplatelet agents were prospectively collected in 17,218 
patients undergoing non-emergent isolated CABG.  The standard information 
collected was the timing of cessation and the agent used.  The timing of aspirin 
cessation was divided into 3 groups; continued to the day of surgery or stopped within 
2 days prior to surgery (late use), stopped between 3 to 7 days prior to surgery (late 
discontinuation), and stopped more than 7 days prior to surgery (early 
discontinuation). 
Exclusion criteria included off-pump CABG, patients on antiplatelet agents 
other than aspirin, patients younger than 18 years of age, previous cardiac operation 
defined as surgical or non-surgical including all forms of percutaneous angioplasty 
and thrombolytic therapy for cardiac indications.  Patients with active infective 
endocarditis were also excluded from this study. 
The primary end points were 30-day and in-hospital mortality, myocardial 
infarction, and stroke.  ANZSCTS definitions of myocardial infarction and stroke 
were used.  Perioperative myocardial infarction is diagnosed by finding at least two of 
the following criteria: enzyme level elevation, new wall motion abnormalities, and 
serial electrocardiogram (at least two) showing new Q waves.  Enzyme level elevation 
requires either creatine kinase-MB > 30 or troponin > 20 micrograms/L.  
Postoperative stroke is defined as a central neurologic deficit persisting for > 72 hours. 
The secondary end points were reexploration for bleeding, drain output for the 
first 4 hours after the operation, total red blood cell (RBC) transfusion, platelet 
transfusion, and coronary reintervention.   
  
Statistical methods 
All analyses were performed with IBM SPSS statistical software. Continuous 
variables are reported as mean ± standard deviations and categorical variables are 
reported as percentages unless otherwise stated. Serum creatinine is in mmol and 
cross clamp and perfusion time in minutes. Student’s t test and one-way ANOVA 
tests were used in univariate analysis of continuous variables. Categorical data was 
analysed using the Pearson’s chi-square test.   
The Cox proportional hazards regression method was used in multivariate 
assessment of differences between groups. We adjusted for pre-operative factors.  
Pre-operative variables included age, sex, body mass index, smoking history, diabetes 
mellitus, peripheral vascular disease, pre-operative serum creatinine, hypertension 
(defined as a blood pressure reading exceeding 140/90 mmHg, a history of high blood 
pressure or need for anti-hypertensive therapy), cerebrovascular disease, left main 
coronary artery disease > 50%, and urgent surgery. Intra-operative factors included 
total cross clamp time, intra-operative anti-fibrinolytic use, number of distal 
anastomoses, use of the left internal mammary artery, right internal mammary artery 
or both and perfusion time. Relative Risks (RR) were estimated, along with their 
associated 95% confidence intervals (CI). Statistical significance was accepted at the 
0.05 level.   
Long term mortality was estimated using Kaplan-Meier survival analysis and 
differences between groups detected via the log – rank test. Survival is reported at 1, 3, 
5, and 7 years after surgery.  
 
RESULTS 
Between June 2001 and December 2012, 16,993 patients taking aspirin 
preoperatively underwent non-emergent isolated CABG.  Of those, 6,814 patients 
(40.1%) continued aspirin use up to the surgery or ceased within 2 days of surgery 
(late use), 3,634 patients (21.4%) stopped their aspirin use between 3 to 7 days prior 
to surgery (late discontinuation), and 6,540 patients (38.5%) stopped their aspirin use 
more than 7 days prior to surgery (early discontinuation).  The demographic, and 
procedural data are included in Table 1. 
The patient characteristics were similar between the late use group, late 
discontinuation group, and early discontinuation group with patients on aspirin in 
regards to age, number of female, body mass index (BMI), smoking history, 
hypertension, diabetes, history of cerebrovascular disease (CVA), peripheral vascular 
disease, and serum Creatinine level.  The rate of left main artery disease tended to be 
higher in the late use group (32.1% versus 23.6% versus 20.0%, respectively).  When 
the urgency of surgery was compared, there were significantly more patients who 
underwent urgent surgery in the late use group than in the other two groups (48.8% 
versus 29.7% versus 17.8%). 
 The use of cardiopulmonary bypass (CPB), total bypass time, total cross 
clamp time, number of anastomoses, use of 1 or 2 internal mammary arteries, and 
intraoperative antifibrinolytic use were similar amongst the three groups. 
 When comparing the end points between the late use group and late 
discontinuation group, the drain output at 4 hours after surgery was significantly 
higher (283.15 ± 294.97 ml versus 243.04 ± 213.21 ml, P<0.001), and the units of red 
blood cells and platelets transfused were significantly higher in the late use group 
(2.89 ± 3.09 versus 2.45 ± 3.28, P<0.001; 1.63 ± 2.39 versus 1.66 ± 12.58, P<0.001, 
respectively) (Table 2).  Though this resulted in increased rate of reoperation for 
bleeding (2.4% versus 2.1%, P=0.001) and return to theatre (5.0% versus 4.3%, 
P<0.001), there was no significant difference regarding the 30 day and in hospital 
mortality (1.4% versus 0.9%, P=0.228; 1.5% versus 1.1%, P=0.454, respectively). 
Similar results were seen when the endpoints were compared between the 
early discontinuation group and late use group (Table 3).  No significant difference 
was noted in regards to 30-day and in hospital mortality.  The drain output at 4 hours 
after surgery was significantly higher (283.15 ± 294.97 ml versus 265.54 ± 286.82 ml, 
P<0.001), and the units of red blood cells and platelets transfused were significantly 
higher in the late use group (2.89 ± 3.09 versus 2.68 ± 3.58, P<0.001; 1.63 ± 2.39 
versus 1.66 ± 12.58, P<0.001, respectively).  The incidence of return to theatre and 
reoperation for bleeding was also higher (5.0% versus 4.1%, P<0.001; 2.4% versus 
2.0%, P<0.001, respectively).  Perioperative myocardial infarction and permanent 
stroke was more commonly seen in the late use group (0.6% versus 0.3%, P=0.002; 
0.8% versus 0.6%, P=0.016, respectively). 
 When comparing the early discontinuation group and late discontinuation 
group, there was no significant difference in 30-day mortality or in-hospital mortality, 
but more incidences of transient and permanent stroke (0.3% versus 0.6%, P=0.031; 
0.6% versus 0.8%, P=0.030, respectively) and perioperative MI (0.3% versus 0.8%, 
P=0.005) were seen in the late discontinuation group (Table 4).  However, the late 
discontinuation group had less drain output (243.04 ± 213.21 ml versus 265.54 ± 
286.82 ml, P=0.006).  
On the other hand, the long term survival tended to be better at 5 and 7 years 
in the late use group compared to late discontinuation and early discontinuation group 
(94.1% versus 93.6% versus 93.3% at 5 years, 93.1% versus 92.0% versus 91.9% at 7 
years), but there was no significant difference (Figure 1). 
 
DISCUSSION 
  The current guideline from STS suggests discontinuation of aspirin 3 to 5 days 
prior to CABG [2].  ACC/AHA guideline has recently changed their 
recommendation from ceasing 7 to 10 days prior to CABG to administering 
preoperatively [3,4].  The recommendations are controversial, and in clinical 
practice, this is also the case.  In our study, approximately 40% of the patients 
undergoing isolated CABG had continued aspirin until less than 2 days prior to 
surgery.  The risk of bleeding intraoperatively and postoperatively leading to 
morbidity and mortality are the foci for discontinuation of aspirin prior to surgery.  It 
has also been previously reported that perioperative red blood cell transfusion is 
associated with significantly reduced long-term survival in patients undergoing 
isolated CABG [11].  STS base the timing of aspirin cessation on platelet physiology.  
Because aspirin is an irreversible cyclooxygenase inhibitor, the life span of a platelet 
(approximately 7 to 10 days) is an important factor in deciding how many days are 
needed to wait for enough new platelets to be formed.  Cessation of aspirin 5 days 
prior to surgery is suggested as it takes 3 to 5 days for half of the platelet pool to be 
regenerated, and this may be enough to normalize bleeding time and thromboxane 
B2 levels. 
The increased amount of postoperative bleeding and the need for red blood 
cells and platelets transfusion were similar to some of the previous literature [5,8,12].  
In this study, the difference of drain output at 4 hours after surgery was approximately 
40 to 60 ml.  This was statistically significant, though may not seem clinically 
significant.  However, the significant difference in transfusion requirements in the late 
use group does suggest clinical relevance.   
Previous large retrospective studies showed no significant difference in the 
drain output postoperatively [13-15].  But Dacey et al. assigned the patients to 
preoperative aspirin group if the patients were exposed to aspirin within 7 days prior 
to surgery [13] and 5 days in the publication by Bybee et al [14].  These data may not 
represent the patients who were on aspirin until the operation.  Dacey et al. compared 
in-hospital deaths with survivors to assess the factors associated with mortality by 
using case patient – control patient methodology [13].  This showed CABG patients 
using preoperative aspirin were less likely to experience in-hospital mortality in 
univariate and multivariate anaysis (odds ratio [OR] = 0.73, 95% confidence interval 
[0.54, 0.97], OR = 0.55, [0.31, 0.98], respectively).  Aspirin use was defined by 
identification of ingestion within 7 days before the operation in this study, therefore, 
this does not represent the patients who were taking aspirin up to the day of surgery.  
Increased drain output was seen in a different large retrospective study by 
Jacob et al. where the patients taking aspirin within 5 days prior to surgery was 
included in the late use group [8].  More recently, Deja et al. showed significant 
increase of bleeding in patients who were loaded with 300 mg of aspirin the night 
before surgery in a randomized trial [12].  In these studies, there was no significant 
difference in mortality or number of reoperations for bleeding.  In our study, the late 
use group were patients who were on chronic aspirin up to less than 2 days prior to 
surgery. 
As early postoperative aspirin administration is known to improve graft 
patency [16] and reduce ischemic complications [1], we did not expect to see more 
perioperative MI in the late use group.  This may be due to the decreased 
haemoglobin or compromised haemodynamic state postoperatively due to the increase 
in bleeding.  This also may be a product of the procoagulant effects of blood products 
or additional protamine given to treat bleeding.  Recommencing of aspirin may have 
been delayed in patients with bleeding complications postoperatively owing to this 
outcome. 
From our results, cessation of aspirin prior to CABG seems to be a reasonable 
decision in elective CABG patients.  Moreover, ceasing 7 days prior to surgery rather 
than 3 to 7 days prior had reduced risk of transient and permanent stroke, and 
perioperative myocardial infarction, which suggests early discontinuation may be the 
preferred choice. 
 The tendency for improved long term survival in the late use group is the only 
supporting result for continuation as this is the key aim when continuing aspirin up to 
the day of surgery.  This could be a late effect of improved graft patency with late use 
of aspirin, though this is only a speculation as routine postoperative angiography was 
not performed.  Deja et al. showed a tendency to decrease the chance of a major 
cardiac event and decreased by 40% the long-term hazard of a coronary event 
developing [12].   
The data used for this study is derived from a very large database compiled 
from multiple institutions, where the decision for aspirin use/cessation is 
surgeon/institution dependent and not regulated by protocol.  Therefore, these results 
are likely to reflect real life practice where there is often high variability. 
Surgeons need to take into consideration the preoperative status of each 
patient when deciding if aspirin needs to be discontinued.  Is an increase in early 
mortality an acceptable price to pay for improved late outcome?  It may well be, 
especially in young patients that are expected to live more than 10 years 
postoperatively.  But in the current state where there is little to no evidence that there 
is improvement in long term outcome, we still need to be cautious in continuing 
aspirin prior to surgery. 
 
Study Limitations 
 We were not able to obtain data regarding the dosage of the preoperative 
aspirin use or the timing of postoperative use of antiplatelets which may have had a 
significant impact on the postoperative outcomes.  We are also unaware of the 
incident rate of ischemic events prior to surgery in those who had their aspirin ceased. 
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Table 1: Patient demographics and intraoperative data 
Characteristic Isolated CABG – Aspirin 
(N=16993) 
  <2 Days 3-7 Days 
(N=3634) 
>7 Days 
(N=6540) (N=6814) 
Age – yr (Mean 
± SD) 
66.36 ± 10.50 66.44 ± 10.07 66.41 ± 10.10 
Sex – female no. 
(%) 
1419 (20.8) 751 (20.7) 1318 (20.2) 
Body Mass 
Index (Mean ± 
SD) 
28.78 ± 7.72 28.89 ± 7.53 29.23 ± 11.78 
Smoking History 
(Current 
Smokers) n, (%) 
4452 (65.4) 2376 (64.4) 4208 (64.4) 
1206 (27.1) 482 (19.6) 878 (20.5) 
Hypertension n, 
(%) 
5429 (79.7) 2971 (81.8) 5284 (80.8) 
Cerebrovascular 
Disease n, (%) 
684 (10.0) 411 (11.3) 700 (10.7) 
Left Main Artery 
Stenosis >50% n, 
(%) 
2186 (32.1) 857 (23.6) 1310 (20.0) 
Diabetes n, (%) 2412 (35.4) 1306 (35.9) 2317 (35.4) 
Peripheral 
Vascular Disease 
n, (%) 
759 (11.1) 434 (11.9) 719 (11.0) 
Preoperative 
Serum 
Creatinine 
(mmol) - Female 
(Mean ± SD) 
(Male) 
1.16 ± 0.39 1.15 ± 0.41 1.16 ± 0.40 
(1.07 ± 0.40) (1.06 ± 0.41) (1.08 ± 0.40) 
Urgent Surgery 
n, (%) 
3324 (48.8) 1078 (29.7) 1164 (17.8) 
Perfusion Time 
(mins) mean ± 
SD 
93.81 ± 33.09 93.36 ± 33.52 90.85 ± 33.98 
Cross Clamp 
Time (mins) 
mean ± SD 
68.30 ± 29.57 66.37 ± 26.57 65.40 ± 31.87 
Total Distal 
Anastomoses 
mean ± SD 
3.35 ± 1.00 3.35 ± (1.00) 3.26 ± 1.01 
LIMA n, (%) 6537 (99) 3485 (99.3) 6205 (99.3) 
RIMA n, (%) 683 (10.4) 309 (8.8) 482 (7.7) 
BIMA n, (%) 666 (9.8) 298 (8.2) 457 (7.0) 
Intraoperative 
Antifibrinolytic 
Use n, (%) 
3887 (79.6) 1671 (75.2) 2957 (75.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Late use versus late discontinuation outcomes 
Aspirin CABG <2 Days 3-7 Days P-value RR 
(N=6814) (N=3634) 
30 Day Mortality n, (%) 94 (1.4) 34 (0.9) 0.381 0.800  
In Hospital Mortality n, (%) 105 (1.5) 39 (1.1) 0.615 0.891  
Drain Losses at 4 hours n, (%) 283.15 ± 
294.97 
243.04 ± 
213.21 
<0.001 0.698  
Units of PRBC Transfused n, (%) 2.89 ± 
3.09 
2.45 ± 
3.28 
<0.001 0.622  
Units of Platelets Transfused n, (%) 1.63 ± 
2.39 
0.9 ± 
2.12 
<0.001 0.484  
Reoperation for Bleeding n, (%) 164 (2.4) 76 (2.1) <0.001 0.524  
Return to Theatre (RTT) n, (%) 338 (5.0) 155 (4.3) <0.001 0.593  
Reoperation for Graft Occlusion n, 
(%) 
5 (0.1) 1 (0.0) 0.539 0.509  
Permanent Stroke n, (%) 54 (0.8) 29 (0.8) 0.876 0.957  
Transient Stroke n, (%) 22 (0.3) 21 (0.6) 0.363 1.421  
Perioperative Myocardial Infarction 
n, (%) 
42 (0.6) 28 (0.8) 0.755 0.903  
 
 
 
 
 
 
Table 3: Early discontinuation versus late use outcomes 
Aspirin CABG >7 Days <2 Days P-value RR 
(N=6540) (N=6814) 
30 Day Mortality n, (%) 58 (0.9) 94 (1.4) 0.174 1.372 
In Hospital Mortality n, (%) 78 (1.2) 105 (1.5) 0.316 1.232 
Drain Losses at 4 hours n, (%) 265. 54 ± 
286.82 
283.15 ± 
294.97 
<0.001 1.614 
Units of PRBC Transfused n, (%) 2.68 ± 
3.58 
2.89 ± 
3.09 
<0.001 1.595 
Units of Platelets Transfused n, (%) 1.66 ± 
12.58 
1.63 ± 
2.39 
<0.001 1.992 
Reoperation for Bleeding n, (%) 130 (2.0) 164 (2.4) <0.001 2.069 
Return to Theatre (RTT) n, (%) 266 (4.1) 338 (5.0) <0.001 1.876 
Reoperation for Graft Occlusion n, 
(%) 
4 (0.1) 5 (0.1) 0.372 0.538 
Permanent Stroke n, (%) 40 (0.6) 54 (0.8) 0.016 2.027 
Transient Stroke n, (%) 18 (0.3) 22 (0.3) 0.213 1.707 
Perioperative Myocardial Infarction 
n, (%) 
22 (0.3) 42 (0.6) 0.002 3.19 
 
 
 
 
 
 
Table 4: Early discontinuation versus late discontinuation outcomes 
Aspirin CABG >7 Days 3-7 Days P-value RR 
(N=6540) (N=3634) 
30 Day Mortality n, (%) 58 (0.9) 34 (0.9) 0.773 1.098 
In Hospital Mortality n, (%) 78 (1.2) 39 (1.1) 0.699 1.098 
Drain Losses at 4 hours n, (%) 265. 54 ± 
286.82 
243.04 ± 
213.21 
<0.001 1.126 
Units of PRBC Transfused n, (%) 2.68 ± 
3.58 
2.45 ± 
3.28 
0.870 0.993 
Units of Platelets Transfused n, (%) 1.66 ± 
12.58 
0.9 ± 
2.12 
0.626 0.964 
Reoperation for Bleeding n, (%) 130 (2.0) 76 (2.1) 0.658 1.085 
Return to Theatre (RTT) n, (%) 266 (4.1) 155 (4.3) 0.403 1.112 
Reoperation for Graft Occlusion n, 
(%) 
4 (0.1) 1 (0.0) 0.25 0.274 
Permanent Stroke n, (%) 40 (0.6) 29 (0.8) 0.03 1.94 
Transient Stroke n, (%) 18 (0.3) 21 (0.6) 0.031 2.425 
Perioperative Myocardial Infarction 
n, (%) 
22 (0.3) 28 (0.8) 0.005 2.882 
 
 
 
 
 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Group 
Number 1 Year 3 Year 5 Year 7 Year 
<2 
Days 
6814 6690 
(124) 
6607 
(207) 
6556 
(258) 
6545 
(269) 
3-7 
Days 
3634 3578 
(56) 
3507 
(127) 
3465 
(169) 
3452 
(182) 
>7 
Days 
6545 6439 
(106) 
6328 
(217) 
6241 
(304) 
6216 
(329) 
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